Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials.
Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials.
复制标题
DOI：
--
复制
发表时间：
2010-07
影响因子：
--
通讯作者：
H. Mizuno
中科院分区：
文献类型：
--
作者：
H. Mizuno
基于干细胞的疗法在各种组织和器官的修复和再生中的潜在用途提供了一种范式转变，可以为几种疾病提供替代治疗方案。胚胎干细胞或诱导多能干细胞的临床应用仍然有限，因为细胞法规，伦理考虑和遗传操作的要求，尽管这些细胞在理论上是非常有益的。脂肪源性干细胞（ASC）似乎是用于实际再生医学的理想干细胞群体，因为它们是丰富的，是自体组织来源的，因此是非免疫原性的，并且由于最小的伦理考虑而更容易获得。虽然ASC起源于中胚层谱系，但最近的临床前研究表明，ASC在再生医学中的应用不仅限于中胚层组织，还可以扩展到外胚层和内胚层组织和器官。本综述总结并讨论了目前在再生医学中使用ASCs的临床前和临床数据，并讨论了这种基于细胞的疗法的未来应用。
The potential use of stem cell-based therapies for the repair and regeneration of various tissues and organs offers a paradigm shift that may provide alternative therapeutic solutions for several diseases. The clinical use of either embryonic stem cells or induced pluripotent stem cells remains limited because of cell regulations, ethical considerations and the requirement for genetic manipulation, although these cells are theoretically highly beneficial. Adipose-derived stem cells (ASCs) appear to be an ideal population of stem cells for practical regenerative medicine, given that they are plentiful, of autologous tissue origin and thus non-immunogenic, and are more easily available because of minimal ethical considerations. Although ASCs originate from mesodermal lineages, recent preclinical studies have demonstrated that the use of ASCs in regenerative medicine is not limited to mesodermal tissue, but can also extend to both exodermal and endodermal tissues and organs. This review summarizes and discusses current preclinical and clinical data on the use of ASCs in regenerative medicine and discusses the future applications of such cell-based therapies.